Imgenex Corp. develops and commercializes novel reagents for the scientific study of human biology and disease and for the production of new diagnostic assays and potential therapies of such diseases. These novel reagents include antibodies, gene and protein expression systems, and arrays of various cells and tissues for use in studies of functional genomics. Areas of biological interest at IMGENEX include cancer, apoptosis (programmed cell death), molecular signaling pathways, cellular aging, and metabolic and infectious diseases.

NF-kB (nuclear factor kB) regulates the expression of a large number of genes that play critical roles in apoptosis, viral replication, tumorigenesis, various autoimmune diseases and inflammation. The active nuclear form of the NF-kB transcription factor complex is composed of two DNA binding subunits, NF-kB p65 and p50, both of which share extensive N-terminal sequence homology with the v-rel oncogene product. N-terminal regions of p50 and p65 are critical for DNA binding and help determine the DNA-binding specificities of p50 and p65.